Bioethics of enhancement

Bioethics of enhancement is the branch of applied ethics that asks whether, and under what conditions, biomedical interventions may be used to raise human capacities above what is typical for the species rather than to restore what disease has taken away. The debate acquired its modern shape around 2000, when genome editing, psychopharmacology, and embryo screening made the question look imminent rather than literary. Two decades later the philosophical positions are well developed and the technologies mostly are not, which gives the literature an unusual character: it is a mature argument about capabilities that largely do not yet exist.

§The line and why it moves

The organising distinction is between therapy, which restores or maintains normal function, and enhancement, which improves on it. The line does real institutional work. Insurers reimburse therapy; medical licensing is justified by therapeutic purpose; most genome-editing statutes permit intervention only for "serious disease" without defining the term.

It also fails under examination. Vaccination does not restore function but adds immunity a person never had. Contraception disables a working system. Caffeine, corrective lenses, and literacy all improve on the unaided baseline. Growth hormone was approved in the United States in 2003 for idiopathic short stature, a condition defined by height alone rather than by any identified pathology — the same molecule, the same effect on the same trait, classified as therapy or enhancement depending on whether a cause was found.¹ The same ambiguity operates in the licensing of GLP-1 weight-loss drugs, approved in the United States in 2021 for chronic weight management in adults above a body-mass threshold, or above a lower threshold with a weight-related condition.² Where that second criterion is absent, the line between treating and improving is drawn by a number rather than by a diagnosis.

Norman Daniels offered the most influential defence of the line: what justice requires medicine to provide is defined by species-typical normal functioning, because departures from it restrict the range of life plans a person can pursue.³ The distinction, on this account, is not about what is natural but about what a society owes. Critics respond that the boundary of the normal is itself statistical and shifting, and that an argument about the limits of entitlement has been repurposed as an argument about the limits of permission. Human enhancement surveys the modalities; this article concerns the arguments about them.

Terminology

"Enhancement" is used in at least three incompatible senses in the literature: any improvement on an individual's prior state, any improvement beyond the species-typical range, and any improvement not justified by a medical indication. Arguments frequently trade on the ambiguity.

§The case against

Leon Kass, chairing the US President's Council on Bioethics from 2001, framed the objection in terms of ends rather than risks. The Council's 2003 report Beyond Therapy accepted that enhancement technologies might work as advertised and argued that this was the problem: better memory, better mood, and longer life pursued as consumer goods would corrode the practices that give those capacities meaning.⁴ Kass had earlier defended the evidential weight of moral disgust — the "wisdom of repugnance" — as a signal that something deep is at stake even when argument cannot articulate it. That move is widely regarded as the weakest part of the case; repugnance has a poor historical record.

Michael Sandel's version is more durable. In The Case Against Perfection he argues that the drive to enhance expresses a refusal of "giftedness" — the recognition that a person's talents are not wholly their own doing — and that three social goods depend on that recognition: humility, limits on responsibility, and solidarity.⁵ If height, temperament, and intelligence become choices, they become someone's fault. Insurance pools rest on shared exposure to luck; remove the luck and the case for pooling weakens. This is an argument about social structure, not about nature, and it does not depend on any claim that the given is good.

Jürgen Habermas adds a claim about moral symmetry: a person who knows their dispositions were selected by their parents to a design stands in an asymmetric relation to those parents that no naturally born person occupies, and this may undermine their standing as an equal author of their own life.⁶ Francis Fukuyama argues that human rights rest on a complex of shared species characteristics he calls Factor X, and that fragmenting it fragments the basis of equal treatment.⁷ These positions are collected under Bioconservatism.

§The case for

John Harris makes the simplest argument: there is no morally relevant difference between preventing harm and conferring benefit. If it is good to cure a child's poor eyesight, it is good to prevent it, and there is no principled point at which improving vision becomes wrong.⁸ Julian Savulescu extends this to reproduction as Procreative beneficence, the claim that prospective parents have reason to select the child expected to have the best life.

Nick Bostrom and Anders Sandberg supply the most useful methodological contribution on the pro-enhancement side, and it cuts against naive optimism. Their evolutionary optimality challenge asks: if this modification is so beneficial, why has evolution not made it? A proposed enhancement is credible only if the proponent can answer — because the environment has changed, because evolution optimises for reproductive fitness rather than wellbeing, or because a developmental constraint blocked the path.⁹ Applied honestly, the heuristic rules out most speculative enhancements and supports a few, which is what a good heuristic should do.

Allen Buchanan's Beyond Humanity? attacks both camps: the bioconservative appeal to nature treats an unplanned evolutionary process as if it were a designer with good judgment, while enthusiasts underrate how much of human capacity is already the product of institutions rather than biology.¹⁰ Much of what is claimed for cognitive enhancement was delivered historically by literacy, nutrition, and public health — the position developed under Intelligence amplification.

§Authenticity and the self

A distinct strand asks whether a chemically or genetically improved trait is really the person's own. Carl Elliott catalogued the unease of patients who did well on antidepressants and felt they had cheated.¹¹ Erik Parens reframed the disagreement as one between two ethical vocabularies — gratitude for what is given, and creativity in remaking it — each internally coherent and neither obviously prior.

The counterargument is that authenticity is not the same as origin. A person who chooses a trait after reflection may own it more fully than one who inherited it. The dispute recurs in every domain the wiki covers: in Deep brain stimulation, where a minority of patients report changes in personality or in the sense of agency; in Moral enhancement, where the thing modified is the faculty that would evaluate the modification; and in Personal identity and continuity, where the question becomes whether the enhanced person is the same person at all.

§Fairness, coercion, and access

The distributive objection is that enhancement bought at market prices entrenches advantage across generations, converting income inequality into biological inequality. It is the strongest argument in practice and the one most often answered with a promise that costs will fall. That promise remains unredeemed for the nearest existing analogue: the organising committee of the 2023 international summit on human genome editing described the cost of licensed somatic gene therapies as unsustainable and called for a commitment to affordable access,¹² and one manufacturer withdrew an approved therapy from the German market in 2021 after reimbursement negotiations failed, later winding down its European operations altogether.¹³ Access and inequality examines the record.

The coercion objection is structurally different and does not require anyone to be excluded. Where an enhancement confers positional advantage, its availability changes the choice set of people who do not want it: surgeons whose colleagues take modafinil, students whose peers do, athletes competing against the pharmacologically prepared. Nobody is forced and everybody's options worsen. This is the subject of Enhancement arms race, and it is the mechanism the anti-doping regime described in Enhancement in sport exists to interrupt.

A third objection comes from disability scholarship: enhancement raises the baseline against which impairment is measured, so that traits currently unremarkable become deficits. Disability rights and enhancement treats this and the related expressivist objection to selection.

The disagreement in one line

Critics argue that enhancement changes what it means to be human and should therefore face a presumption against it; proponents reply that the presumption smuggles in the assumption that the current human is well designed, which nobody defends when asked directly.

§The empirical gap

The literature's most striking feature is how little of it is constrained by evidence. Cognitive pharmacology has produced no agent with a reliable effect on healthy adults beyond wakefulness; the evidence base is reviewed in Nootropics. Transcranial direct-current stimulation, for a decade the leading non-invasive enhancement candidate, has a poor replication record, as Non-invasive neuromodulation describes. Polygenic embryo screening delivers expected gains that are real but small and poorly characterised outside the ancestry groups its predictors were trained on. Genetic enhancement of cognition is limited by the fact that the trait is spread across thousands of variants of tiny effect, each with unknown pleiotropic consequences.

Two of the field's founding worries have meanwhile been tested. The He Jiankui affair showed what happens when a researcher acts outside professional constraint — not a slippery slope but a single episode, prosecuted, and not since repeated in any case that has become public. The organising committee of the 2023 summit reported that heritable editing remained unacceptable, on the ground that neither the safety standards nor the governance frameworks for it were in place.¹² And the enhancement that reached paying customers first arrived through selection rather than editing, which almost no pre-2010 framework anticipated and which most regulatory instruments still do not reach.

§Open problems

Three questions remain genuinely unsettled rather than merely contested.

Who decides what counts as better. Enhancement presupposes a direction of improvement. For visual acuity or infection resistance the direction is uncontroversial. For temperament, risk tolerance, or empathy it is not, and the people choosing are usually parents choosing for someone who does not exist yet and cannot object — the structure examined under Designer babies.

Whether the therapy line can be replaced. If it cannot be defended philosophically but is doing necessary institutional work, the alternative is a substantive account of which capacities societies should underwrite and which they should merely permit. No such account commands agreement, and regulators continue to use a distinction that most ethicists on both sides regard as incoherent.

Whether the debate has been about the right technologies. Twenty-five years of argument concentrated on germline modification and cognitive drugs. The interventions that have most visibly changed what people can do in that period are digital rather than biological, and the questions they raise — who has access to a capable external system, and what dependence on one does to the capacities it supplements — sit outside the vocabulary the literature built. That is the territory of Human–AI merger, which the enhancement literature has barely begun to metabolise.

§See also

• Human enhancement
• Bioconservatism
• Procreative beneficence
• Disability rights and enhancement
• Enhancement arms race
• Moral enhancement
• Leon Kass
• Julian Savulescu

§References

Footnotes

1. paperCuttler, L. and Silvers, J.B. "Growth hormone treatment for idiopathic short stature: implications for practice and policy." Archives of Pediatrics and Adolescent Medicine, 2004. ↩

2. regulatorUS Food and Drug Administration. "FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014." 4 June 2021.↩A marketing approval, which records the indication and the eligibility criteria; it is not evidence about how the drug is used off-label.

3. paperDaniels, N. "Normal Functioning and the Treatment-Enhancement Distinction." Cambridge Quarterly of Healthcare Ethics, 2000. ↩

4. reportPresident's Council on Bioethics. Beyond Therapy: Biotechnology and the Pursuit of Happiness. Washington, DC, 2003.↩An advisory report to a US president, written by appointees of the administration that convened the council, not by a scientific consensus body.

5. bookSandel, M. The Case Against Perfection: Ethics in the Age of Genetic Engineering. Harvard University Press, 2007. ↩

6. bookHabermas, J. The Future of Human Nature. Polity Press, 2003. ↩

7. bookFukuyama, F. Our Posthuman Future: Consequences of the Biotechnology Revolution. Farrar, Straus and Giroux, 2002. ↩

8. bookHarris, J. Enhancing Evolution: The Ethical Case for Making Better People. Princeton University Press, 2007. ↩

9. bookBostrom, N. and Sandberg, A. "The Wisdom of Nature: An Evolutionary Heuristic for Human Enhancement." In Human Enhancement, Oxford University Press, 2009.↩A book chapter arguing a heuristic from evolutionary reasoning rather than reporting experiments; it concerns what is plausible, not what has been shown to work.

10. bookBuchanan, A. Beyond Humanity? The Ethics of Biomedical Enhancement. Oxford University Press, 2011. ↩

11. bookElliott, C. Better Than Well: American Medicine Meets the American Dream. W. W. Norton, 2003.↩Reporting and cultural criticism drawn from interviews and clinical anecdote, not a study of outcomes.

12. statementOrganising Committee of the Third International Summit on Human Genome Editing. "Statement from the Organising Committee." London, March 2023.↩ ↩²A summary of the organisers' conclusions from a three-day meeting, not a consensus report reviewed by the convening academies.

13. statementbluebird bio. Announcement of the withdrawal of Zynteglo from the German market following reimbursement negotiations, April 2021, and of the wind-down of the company's European operations, October 2021.↩A company speaking about its own commercial decision; it records that the withdrawal happened and the reason given, not an independent account of the negotiations.